Authors
Latest:
Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of DiseaseDrs. Kato and Kurzrock discuss the potential reasons why some cancer patients experience hyperprogression of disease while on immunotherapy treatment.
Latest:
Highlights of USPSTF Updates to Prostate Cancer Screening GuidelinesUSPSTF Vice-Chair Alex Krist and prostate cancer specialist David Penson shared perspectives on USPSTF’s updated prostate cancer screening recommendation.
Latest:
Quiz: The Role of CAR T Cells in Multiple MyelomaHow much do you know about the role of CAR T cells in multiple myeloma? Here's your chance to find out.
Latest:
How Does Pre-emptive Plerixafor Affect Stem Cell Mobilization for Myeloma Transplant?A new study suggests there is a cost and efficiency benefit to pre-emptively administrating plerixafor during stem cell collection.
Latest:
Updates on Genetic Testing in Breast CancerIn this video, Dr. Allison Kurian discusses polygenic risk scores, genetic testing in diverse populations, and more as they relate to breast cancer.
Latest:
Managing Adverse Effects in Patients with HER2+ Breast CancerHarold J. Burstein, MD, PhD, discusses the management of adverse events in patients with HER2+ breast cancer, and the Oncology Brothers provide closing thoughts on the entire discussion.
Latest:
A 79-Year-Old Man on Nivolumab with Itchy Erythematous PatchesA 79-year-old white man presented with an ulcerated chest wall lesion developing from an existing mole.
Latest:
E. David Crawford, MD, Reviews Unmet Needs Addressed by FDA Approval of Darolutamide, Docetaxel, and ADT in mHSPCIn an interview with CancerNetwork®, E. David Crawford, MD, discussed implications from the recent FDA approval of darolutamide plus docetaxel and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer based on findings from the phase 3 ARASENS trial.
Latest:
CAR T-Cell Therapy in ALL: Formidible Challenges RemainAt the NCCN Annual Conference, Dr. Bijal Shah of Tampa’s Moffitt Cancer Center highlighted ongoing challenges in administration of CAR T-cell therapy.
Latest:
Treatment Options Expanding in Renal CarcinomaFirst- and second-line treatment of clear cell RCC has changed dramatically, Dr. Eric Jonasch said during the NCCN Annual Conference in Orlando.
Latest:
Response and Development of Immune-Related Adverse Events in an 83-Year-Old Man With Metastatic Urothelial CancerAn 83-year-old man was diagnosed with multiple low-grade transitional cell carcinomas over a 6-year period. A surveillance cystoscopy in year 7 showed high-grade noninvasive papillary urothelial carcinoma in the bladder trigone. A CT urogram showed a soft-tissue mass with diffuse enhancement in the lower pole of the left kidney, concerning for malignancy.
Latest:
Eileen Parkes on Why Cancer Researchers Are Excited About STING AgonistsONCOLOGY recently interviewed Dr. Eileen Parkes, whose laboratory studies the STING pathway, to find out why researchers are excited about targeting this pathway as a potential cancer therapy.
Latest:
The Use of Surgery and Radiotherapy as Treatment of Regional Nodes in Breast Cancer PatientsThis article discusses the ways in which pathologic regional nodal status affects clinical decisions about locoregional and systemic treatment, reviews published literature and guidelines, and aims to provide a practical perspective on treatment approach in the face of a broad range of data and recommendations.
Latest:
Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular TherapiesHere we focus on alternative methods of harnessing both adaptive and innate antitumor immunity to target prostate cancer cells, and look ahead to provide a perspective on how this growing collection of immunotherapeutic approaches may ultimately be combined to target prostate cancer from a variety of angles.
Latest:
Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular TherapiesHere we focus on alternative methods of harnessing both adaptive and innate antitumor immunity to target prostate cancer cells, and look ahead to provide a perspective on how this growing collection of immunotherapeutic approaches may ultimately be combined to target prostate cancer from a variety of angles.
Latest:
Everolimus Plus Letrozole Effective in Endometrial CarcinomaFindings from the GOG-3007 study suggest everolimus plus letrozole might be effective in advanced persistent or recurrent endometrial carcinoma.
Latest:
Updates to the US Preventive Services Task Force Guideline on Ovarian Cancer ScreeningIn this interview, Dr. Stephanie Blank discusses the recently released updates to the US Preventive Services Task Force Guideline on Ovarian Cancer Screening, and how patients and clinicians should interpret them and take action.
Latest:
45-Year-Old Female With Gross Hematuria Post Partial NephrectomyA 45-year-old female presents with gross hematuria 5 days after a laparoscopic partial nephrectomy for renal cell cancer. What is your diagnosis?
Latest:
Evaluating Two RT-Plus-Chemotherapy Strategies in Bladder Cancer Patients Undergoing Bladder SurgeryIn this interview, we spoke with John J. Coen, MD, a radiation oncologist who presented results at the 2018 Genitourinary Cancers Symposium of a phase II study exploring two different radiation-plus-chemotherapy combination strategies in patients undergoing bladder surgery for their tumors.
Latest:
HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast CancerTucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.
Latest:
Protecting Breast Cancer Patients From Cardiac Adverse Effects of Treatment With Anthracyclines and HER2-Targeted TherapiesDuring the 2018 Miami Breast Cancer Conference, cardiologist Dr. Jean-Bernard Durand discussed protecting patients who are being treated with anthracyclines and HER2-targeted therapies from serious cardiac adverse events.
Latest:
Jeffrey Weber, MD, PhD, Describes Unmet Needs for Patients with MelanomaJeffrey Weber, MD, PhD, discusses the unmet needs professionals take into consideration when deciding treatment options for patients with melanoma.
Latest:
Effective Palliative Care: What Is Involved?This article reviews the ways in which palliative care and oncology teams can collaborate to provide high-quality care to patients and their families; it also provides practical tips for oncologists who wish to initiate primary palliative care for their patients.
Latest:
Effective Palliative Care: What Is Involved?This article reviews the ways in which palliative care and oncology teams can collaborate to provide high-quality care to patients and their families; it also provides practical tips for oncologists who wish to initiate primary palliative care for their patients.
Latest:
Utility of the 21-Gene Recurrence Score in Node-Positive Breast CancerABSTRACT The 21-gene Recurrence Score (RS) assay has been validated as both a prognostic and predictive tool in node-negative (pN0), estrogen receptor–positive (ER+), HER2-negative (HER2–) breast cancer. A large body of evidence supports the clinical utility of the RS in the node positive (pN+) population as well. Retrospective analyses of archived tissue from multiple clinical trials have found the RS to be prognostic in both endocrine therapy (ET)-treated and chemotherapy-treated patients with pN+ disease. Distribution of RS results in pN+ patients have also been consistent with those of pN0 populations. Data from the SWOG 8814 trial and large population-based registries further support the prognostic and potential predictive value of the RS. Specifically, patients with 1 to 3 positive nodes and RS less than 18 derived negligible benefit from adjuvant chemotherapy in these studies. In the prospective West German Study Group PlanB and ADAPT trials, pN+ patients with RS less than 11 and RS ≤25, respectively, who were treated with ET alone experienced excellent outcomes. Finally, 5-year results of the RxPONDER clinical trial randomizing patients with 1 to 3 positive nodes and RS ≤25 to ET alone vs ET plus chemotherapy confirmed an absence of chemotherapy benefit in postmenopausal patients. Clinical practice guidelines support use of the RS in the pN+, ER+/HER2– population, and many institutions have adopted the RS to guide clinical decision-making, resulting in a net reduction of adjuvant chemotherapy use. This review highlights the existing data supporting the prognostic and predictive ability of the RS in pN+ disease, current practice patterns related to RS use in this population, and emerging applications.
Latest:
POINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer PatientsReversible ovarian function suppression using LHRH agonists is the preferred first treatment for most premenopausal breast cancer patients.
